scholarly journals The Demographic, Clinical and Survival Rate of Classical Hogkings Lymphoma Patients in Oman, Retrospective Study

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5369-5369
Author(s):  
Khalid Nasser Al Hashmi ◽  
Kamla Alwahaibi ◽  
Murtadha K. Al-Khabori
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Hodgkin’S Lymphoma ◽  
Conflicts Of Interest ◽  
Tertiary Care ◽  
Survival Rates ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Lymph Node Enlargement ◽  
Tertiary Care Centers

Abstract Background and Objectives Hodgkin's lymphoma (HL) is a B cell lymphoma characterized by the presence of Reed-Sternberg cells. HL comprises 1% of all cancer cases and 14% of all lymphoma cases. The clinical presentation and survival rate of these patients have not been described in Oman. We, therefore, aimed to describe the clinical characteristics and survival rate of patients with classical Hodgkin's lymphoma. Methods This is a retrospective study that was conducted in a tertiary care centers in the Sultanate of Oman. All Omani adults with histopathological confirmed diagnosis of classical Hodgkin's lymphoma from 2000 to 2016 were included in this study. The demographic, clinical, and survival rate were recorded and analyzed. Results A total of 273 patients (45 % females and 55% males, mean age 32) fulfilled the inclusion criteria with histopathological confirmed diagnosis of classical Hodgkin's lymphoma. The commonest presenting feature was lymph node enlargement (83%); followed by fever (48%). The most common classical HL histological subtype was nodular sclerosing HL (NSHL) (71%). The most common stage was II 34%. The most common chemotherapy regimen used as the first line was doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) (89%). Five and 10-year survival rates were 93.8 % and 99.2%, respectively. Conclusions This is the first study that demonstrates the demographic, clinical and survival rate of HL patients in Oman, and provides a general picture of the HL patients in our country. Disclosures No relevant conflicts of interest to declare.

Outcome of Young Children with Non-Hodgkin's Lymphoma

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 5106-5106
Author(s):  
Laura Rodriguez ◽  
Mohammed Zolaly ◽  
Sheila Weitzman ◽  
Ahmed Naqvi ◽  
Angela Punnet ◽  
...  
Keyword(s):  
Young Children ◽  
Hodgkin’S Lymphoma ◽  
Conflicts Of Interest ◽  
Cell Lymphoma ◽  
Organ Transplant ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Abstract 5106 Background: The incidence and biology of non-Hodgkin's lymphoma (NHL) vary according to age, and the outcome differs amongst children being less favorable in infants and adolescents. Objectives: To analyze the outcome and toxicity patterns of young children with NHL comparing patients aged < 10 years to those 10–18 years of age. Methods: A retrospective review of children ≤ 18 years of age diagnosed with NHL over a period of 13 years. Patients were treated according to different protocols and treatment subgroups included: Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), lymphoblastic lymphoma (LL), anaplastic large cell lymphoma (ALCL), and peripheral T-cell lymphoma (PTCL). Post-organ transplant lymphoproliferative disorder (PTLD) and immunodeficient patients were excluded. Results: From 01/1995 to 12/2008, 173 children with NHL were reviewed. Of these, 81 pts (47%) were <10 years of age, with BL (29 pts), DLBCL (5 pts), PTCL (6 pts), LL (27 pts), and ALCL (14 pts). The 10-year overall survival (OS) was 93. 6+2. 8% in patients aged < 10 years compared to 77. 3+7. 2 in patients 10–18 years of age (P=0. 02). The 10-year event-free survival (EFS) was 89. 4+3. 5% in patients aged < 10 years compared to 70+9. 3% in patients 10–18 years of age (P=0. 03). BL was the most common subtype in patients <10 years, with a 10-year EFS of 96. 4+3. 5% versus 82. 6+7. 9% in patients 10–18 years of age (P=0. 10). The most common subtype in patients 10–18 years of age was ALCL (36%), the 10-year EFS was 78. 5+8. 3 versus 92. 9+6. 9 in patients < 10 years (P=0. 29). Children 10–18 years of age were more likely to develop neurotoxicity (9. 7% vs 0%), gastrointestinal toxicity (30% vs 12%), and treatment-related mortality (4. 3% vs 2. 4%). Conclusions: Children < 10 years with NHL have better outcomes and less treatment-related toxicity than older children. Disclosures: No relevant conflicts of interest to declare.

DLBCL with CD30+ Has Not a Better Prognosis in a Brazilian Coorte Population

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5014-5014
Author(s):  
Talita Rocha ◽  
Carlos Sérgio Chiattone ◽  
Ana Beatriz Kinupe ◽  
Felipe Costa ◽  
Jose Vassalo ◽  
...  
Keyword(s):  
Overall Survival ◽  
Hodgkin’S Lymphoma ◽  
Conflicts Of Interest ◽  
Cell Lymphoma ◽  
Disease Free Survival ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Anatomic Site ◽  
Large Cell Lymphoma

Abstract Background: CD30 is a well-known diagnostic marker in both anaplastic large cell lymphoma (ALCL) and classical Hodgkin's lymphoma (CHL). The chimeric drug brentuximab vedotin that combines an anti-CD30 monoclonal antibody with the anti-tubulin agent monomethyl auristatin E demonstrated activity in patients with relapsed CHL, ALCL and other lymphomas that express CD30+. Previous observational studies have suggested that CD30 may be expressed in 10 to 20% of DLBCLs. It is possible that CD30+ DLBCLs may show different biologic behavior and be amenable to anti-CD30 therapy. The aim of this study was to determine the prevalence of CD30 expression in DLBCL by immunohistochemistry and explore possible relationships with important clinical and biologic variables of DLBCL. Methods: We retrospectively identified cases of DLBCL diagnosed between Jan 2007 and march 2014 at our institution. Eligible cases included patients with diagnosis of DLBCL irrespective of anatomic site or tumor stage. The diagnosis of DLBCL was based on the current WHO 2008 criteria. The following large B cell lymphoma subtypes were excluded from this analysis: post-transplant lymphoproliferative disorders with DLBCL morphology, Primary Mediastinal large cell lymphoma and the unclassifiable lymphomas with features intermediate between either DLBCL and Burkitt's lymphoma or between DLBCL and Hodgkin's lymphoma. Immunohistochemistry was performed with TMA (tissue microarray) in all the cases. We use a cut-off of 0%, 5% (expression between 0 and 10%), 10% and 20%. DLBCLs were classified into germinal center (GC) or non-GC subtypes applying the Hans algorithm. Logistic regression analysis was performed to assess association between selected variables and CD30 expression. Results: A total of 197 cases of DLBCL were eligible for this study and of these 152 cases (77.1%) had paraffin material available to analyse CD30. Clinical and laboratory characteristics of all coorte are shown bellow(table 1). Fifty one patients (33,5%) were positive for CD30, using cut-off>0% and 16 pacients (10,5%) were positives with a cut off ≥ 20%. Nine patients (5,9%) were EBV positives and excluded from the survival analyses. With a follow-up of 34,3 months, according disease free survival, with a cutt off CD30>0%, that was no difference between the groups (71,3% versus 71% p 0,974). According cell origen, no difference was found in the subgroup GC (75% versus 72% p 0,726) nor APC (68,8% versus 64,4% p 0,397). Using cut off CD30 ≥ 20% that was also no difference in DFS between groups (75% versus 70,5% p 0,945). Also ocurred when we analysed cell origen, GC with or without CD30 (75% versus 72,7% p 0,519) and for patients ABC with or without CD30 (75% versus 64,2% p 0,524) . Acoording overall survival, using cutt-off CD30% >0% there was no difference between the groups (86,9% versus 78,2% p 0,257). GC cell origen patients with CD30+ did not have better outcomes than patients CD30- (81,3% versus 77,1% p 0,792). For patients with ABC tumor, there was a slightly better survival for patients with CD30+ (92,3% versus 74,9% p 0,059). Using cut off CD30 ≥ 20% same results were found according CD30 expression. No difference in overall survival (87,1% versus 80,3% p 0,908). Even versus 78,7% p 0,292) nor ABC (90,9% versus 79,8% p 0,384). Conclusion: In this present study, DLBCL with CD30+, using cut-off of 0% or 20% did not shown any difference in DFS or overall survival. Disclosures No relevant conflicts of interest to declare.

scholarly journals HIV-Related Primary Diffuse Large B Cell Lymphoma of the Appendix. What Can We Learn?

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5423-5423
Author(s):  
Michelle Janania Martinez ◽  
Adolfo E Diaz ◽  
Cynthia Forker
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Conflicts Of Interest ◽  
Cell Lymphoma ◽  
Clinical Signs ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Limited Data ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract BACKGROUND: The introduction of antiretroviral therapies has decreased the incidence of HIV associated Non Hodgkin's Lymphoma (NHL), and the median CD4 count on diagnosis has increased; however, the overall aggressive nature of HIV associated NHL has not changed. The gastrointestinal tract is the most common location for extranodal lymphomas, but primary appendiceal lymphoma (PAL) is extremely rare and represents only 0.015% of all gastrointestinal lymphomas. There is limited data on management of these patients; therefore, herein we present a review of the available literature along with our own, and first reported case to our knowledge, of HIV associated Primary Diffuse large B-cell lymphoma (DLBCL) of the appendix . METHODS: We did a detailed literature review using the PubMed and MEDLINE database for published cases of primary appendiceal lymphoma from 1973 to 2018 and found only 125 cases of PAL. We decided to exclude the following histologies due to their significantly different prognosis and management: mucosa-associated lymphoid tissue, Hodgkin's lymphoma and extraosseous plasmacytomas. Demographics (age, gender), tumor histology and clinical characteristics (presentation and management) were assessed. All patients with appendiceal lymphoma were categorized using the 2016 WHO classification of mature lymphoid neoplasms. This was in response to a case encountered at our institute where a 38-year-old woman with controlled HIV presented with right iliac fossa pain and findings of appendicitis found to have DLBCL in the appendix. RESULTS AND DISCUSSION PAL primarily afflicts males, the mean age has been shown to be around 54 years (range: 40-62 years) and usually presents clinically as appendicitis. Out of the total 125 cases of PAL reviewed, the most common histological type was DLBCL (34.4%- 43 cases) followed by Burkitt's (27.2%-34 cases). None of them have been reported as HIV associated. Our patient had the classic presentation of acute appendicitis (by clinical signs/symptoms and by imaging) and diagnosis was made post operatively. Our patient was 38 years old which is significantly younger than the expected range. The optimal treatment for intestinal lymphomas, let alone appendiceal lymphomas, has not been established yet. Most cases previously reported received appendectomy with adjuvant chemotherapy and had no disease recurrence at reported follow-up times. Our patient presented emergently with appendicitis and therefore underwent surgical resection prior to diagnosis of lymphoma, we then elected to proceed with adjuvant EPOCH-R based on efficacy data in the HIV population as per Sparano group. She had no evidence of disease elsewhere and has tolerated the chemo-immunotherapy selected with minimal hematologic toxicities, as expected. CONCLUSION We describe here a rare case of primary appendiceal lymphoma in a young patient with underlying HIV infection. Treatment of patients like ours is very challenging as there are no prior reported cases of HIV associated PAL and therefore no standard guidelines. There is limited data for PAL in general and further studies are required to determine natural course of disease and appropriate treatment protocols. After multidisciplinary discussion and review of limited literature decision was made to proceed with adjuvant EPOCH-R. Disclosures No relevant conflicts of interest to declare.

Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma

2006 ◽  
Vol 24 (25) ◽  
pp. 4123-4128 ◽  
Author(s):  
François Boué ◽  
Jean Gabarre ◽  
Christian Gisselbrecht ◽  
Jacques Reynes ◽  
Antoine Cheret ◽  
...  
Keyword(s):  
Survival Rate ◽  
B Cell ◽  
Phase Ii ◽  
Hodgkin’S Lymphoma ◽  
Phase Ii Trial ◽  
International Prognostic Index ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Purpose To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma. Patients and Methods HIV-seropositive patients with high-grade lymphoma of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/μL, prior AIDS, or performance status less than 2. This multicenter phase II trial evaluated the response rate and disease-free survival after six courses of rituximab plus CHOP. Results Sixty-one patients were enrolled. All the patients were assessable for safety and 52 were assessable for the tumor response after treatment completion. Characteristics of patients were median age, 41 years; median CD4 cells, 172/μL; histology, diffuse large B-cell lymphoma (n = 42), immunoblastic (n = 2), Burkitt lymphoma (n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27). Grade 3 or 4 toxicity consisted of febrile neutropenia in nine patients, anemia in 16 patients, and thrombocytopenia in five patients. Complete remission (CR) or unconfirmed CR was achieved in 40 of the 52 assessable patients, partial remission was achieved in five patients, and seven patients experienced progression. Forty-three patients were alive after a median follow-up of 33 months. The estimated 2-year overall survival rate was 75% (95% CI, 64% to 86%). Eighteen patients died: 16 as a result of lymphoma, one as a result of infection, and one as a result of encephalitis. Conclusion Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.

Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.

1988 ◽  
Vol 6 (1) ◽  
pp. 128-141 ◽  
Author(s):  
M Shimoyama ◽  
K Ota ◽  
M Kikuchi ◽  
K Yunoki ◽  
S Konda ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Survival Rate ◽  
T Cell ◽  
Hodgkin’S Lymphoma ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Hodgkin's Lymphoma ◽  
Free Survival ◽  
Non Hodgkin's Lymphoma ◽  
Disease Free

One hundred sixty-three patients with advanced non-Hodgkin's lymphoma including adult T cell leukemia/lymphoma (ATL) were treated from 1981 to 1983 with VEPA (vincristine, cyclophosphamide, prednisolone, and doxorubicin) or VEPA-M (VEPA plus methotrexate) in randomized fashion after stratification by surface marker. The complete response (CR) rate and the 4-year survival rate of patients treated with VEPA-M was 62.2% and 36.9%, respectively, while for those treated with VEPA the rates were 51.9% and 26.6, respectively. The difference was not statistically significant, but pretreatment characteristics predictive for response and survival were interesting. Three factors, leukemic change, poor performance status (PS), and T cell marker, were negatively associated with both CR and survival rates, and high-grade pathology was adversely associated with survival rate in a multivariate analysis. These prognostic factors are somewhat different from those in Western lymphomas. This may be reflection of major differences in patients' characteristics between Japanese and Western lymphomas: in this study, there was a high incidence of T cell lymphoma/leukemia (50%) including ATL (33%), leukemic manifestation (34%), poor PS (34%), and a low incidence of follicular lymphoma (9%). The statistically significant three factors for both CR and survival rates were used to construct a model containing eight categories of patients at increasing risk for poor response and shortened survival. These categories were divided into four groups, with respective CR and 4-year survival rates of 91% and 73%, 67% and 35%, 27% and 7%, and 10% and 5%. Ninety-three patients in whom CR was induced by VEPA or VEPA-M therapy were evaluated for prognostic factors predictive for disease-free survival. A shorter period (less than 28 days) required to achieve CR, a clinical diagnosis of ATL, and a lower hemoglobin level were found to affect disease-free survival adversely. These results have important implications for both the design of prospective randomized therapeutic trials and the determination of optimal therapy for individual patients.

scholarly journals Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma

2021 ◽  
Vol 9 (2) ◽  
pp. e002097
Author(s):  
Kathryn Lurain ◽  
Ramya Ramaswami ◽  
Ralph Mangusan ◽  
Anaida Widell ◽  
Irene Ekwede ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Hiv And Aids ◽  
Hodgkin's Lymphoma ◽  
People Living With Hiv ◽  
Oncogenic Viruses ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

BackgroundNon-Hodgkin’s lymphoma (NHL) is currently the most common malignancy among people living with HIV (PLWH) in the USA. NHL in PLWH is more frequently associated with oncogenic viruses than NHL in immunocompetent individuals and is generally associated with increased PD-1 expression and T cell exhaustion. An effective immune-based second-line approach that is less immunosuppressive than chemotherapy may decrease infection risk, improve immune control of oncogenic viruses, and ultimately allow for better lymphoma control.MethodsWe conducted a retrospective study of patients with HIV-associated lymphomas treated with pembrolizumab±pomalidomide in the HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute.ResultsWe identified 10 patients with stage IV relapsed and/or primary refractory HIV-associated NHL who were treated with pembrolizumab, an immune checkpoint inihibitor, with or without pomalidomide. Five patients had primary effusion lymphoma (PEL): one had germinal center B cell-like (GCB) diffuse large B cell lymphoma (DLBCL); two had non-GCB DLBCL; one had aggressive B cell lymphoma, not otherwise specified; and one had plasmablastic lymphoma. Six patients received pembrolizumab alone at 200 mg intravenously every 3 weeks, three received pembrolizumab 200 mg intravenously every 4 weeks plus pomalidomide 4 mg orally every day for days 1–21 of a 28-day cycle; and one sequentially received pembrolizumab alone and then pomalidomide alone. The response rate was 50% with particular benefit in gammaherpesvirus-associated tumors. The progression-free survival was 4.1 months (95% CI: 1.3 to 12.4) and overall survival was 14.7 months (95% CI: 2.96 to not reached). Three patients with PEL had leptomeningeal disease: one had a complete response and the other two had long-term disease control. There were four immune-related adverse events (irAEs), all CTCAEv5 grade 2–3; three of the four patients were able to continue receiving pembrolizumab. No irAEs occurred in patients receiving the combination of pembrolizumab and pomalidomide.ConclusionsTreatment of HIV-associated NHL with pembrolizumab with or without pomalidomide elicited responses in several subtypes of HIV-associated NHL. This approach is worth further study in PLWH and NHL.

scholarly journals Survival Rate of 1008 Short Dental Implants with 21 Months of Average Follow-Up: A Retrospective Study

2020 ◽  
Vol 9 (12) ◽  
pp. 3943
Author(s):  
João Caramês ◽  
Ana Catarina Pinto ◽  
Gonçalo Caramês ◽  
Helena Francisco ◽  
Joana Fialho ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Survival Rate ◽  
Dental Implants ◽  
Cox Regression ◽  
Survival Rates ◽  
High Survival ◽  
Implant Survival ◽  
Posterior Maxilla ◽  
Clinical Records

This retrospective study evaluated the survival rate of short, sandblasted acid-etched surfaced implants with 6 and 8 mm lengths with at least 120 days of follow-up. Data concerning patient, implant and surgery characteristics were retrieved from clinical records. Sandblasted and acid-etched (SLA)-surfaced tissue-level 6 mm (TL6) or 8 mm (TL8) implants or bone-level tapered 8 mm (BLT8) implants were used. Absolute and relative frequency distributions were calculated for qualitative variables and mean values and standard deviations for quantitative variables. A Cox regression model was performed to verify whether type, length and/or width influence the implant survival. The cumulative implant survival rate was assessed by time-to-event analyses (Kaplan–Meier estimator). In all, 513 patients with a mean age of 58.00 ± 12.44 years received 1008 dental implants with a mean follow-up of 21.57 ± 10.77 months. Most implants (78.17%) presented a 4.1 mm diameter, and the most frequent indication was a partially edentulous arch (44.15%). The most frequent locations were the posterior mandible (53.97%) and the posterior maxilla (31.55%). No significant differences were found in survival rates between groups of type, length and width of implant with the cumulative rate being 97.7% ± 0.5%. Within the limitations of this study, the evaluated short implants are a predictable option with high survival rates during the follow-up without statistical differences between the appraised types, lengths and widths.

Utility of PET/CT for therapy response assessment in non-Hodgkin's lymphoma

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Sally Mahmoud Abdel-Aziz Abdel-Aziz ◽  
Safaa Kamal Mohamed BadrElden ◽  
Asmaa Magdy Mohamed Salama
Keyword(s):  
Ct Scan ◽  
Hodgkin’S Lymphoma ◽  
B Cell Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Whole Body ◽  
Non Hodgkin’S Lymphoma ◽  
Contrast Enhanced Ct ◽  
Pet Ct ◽  
Non Hodgkin's Lymphoma ◽  
Enhanced Ct

Abstract Aim of the study to evaluate the role of PET/CT in initial diagnosis and staging of lymphoma, and to determine the predictive value of 18F-FDG PET by monitoring the early response and final response after completion of chemotherapy in patients with non-Hodgkin's lymphoma. Patient and Methods our prospective study included 25 patients with pathologically confirmed nonHodgkin Lymphoma diffuse large B cell lymphoma selected from Department of Radiology at Ain Shams University Hospital from January 2019 to March 2020. The patients included in this study performed the followings: Initial PET/CT for staging, interim PET/CT and end of the treatment PET/CT. We performed low dose non enhanced CT scan first, then a whole body PET study followed by diagnostic enhanced whole body CT scan. The whole study took approximately 20-30 minutes. Results PET/CT has greater sensitivity 100% and specificity 68.8% than CT alone for detecting sites of nodal and extra-nodal involvement and for assessment of therapeutic response in non-Hodgkin lymphoma. Conclusion PET / CT is an accurate method for evaluating tumor viability in the post-therapy setting of Non-Hodgkin lymphomas. PET / CT has a significant advantage for the diagnosis of diffusely infiltrating organs without mass lesions or contrast enhancement compared to contrast enhanced CT.

Sign in / Sign up

Export Citation Format

Share Document